From the publishers of JADPRO

MPN Resource Center

Advertisement

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

Last Updated: Wednesday, June 1, 2022

Using medical record data from 200 patients with myelofibrosis in the United Kingdom, researchers determined that, at diagnosis, symptoms and prognostic scores were poorly documented and patient-reported outcome measures were not frequently used. For the majority of patients (53.5%), watch and wait was the first management strategy used, with hydroxycarbamide and ruxolitinib being the most commonly used active treatments. Further, only 5% of patients proceeded to allogeneic transplant.

Therapeutic Advances in Hematology
Advertisement
News & Literature Highlights
Advertisement
Advertisement